This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

eleva GmbH


Eleva uses its proprietary moss cell culture (Bryotechnology) to deliver highly complex and difficult to express biopharmaceuticals with an optimized human-like glycosylation, whereas the first moss-based protein was successfully tested in a clinical trial. Bryotechnology platform: Bryotechnology offers a highly robust production platform, which can be run in state of the art bioreactors in a wide range of temperature and pH conditions. Stability, consistency and homogeneity regarding to N-glycosylation denotes remarkable and is less affected by process conditions and scale. The GMP compliant system can be easily transferred and is known for its batch-to-batch stability and safety. Due to simple culture media and the avoidance of virus-filtration systems, even demanding proteins can be produced in a cost efficient manner. CPV-104: broad preclinical testing completed (dry AMD, PNH, C3G, ANCA, Lupus nephritis) Tox-studies ongoing, potential treatment for several complement indications. RPV-001: recombinant enzyme alpha-Galactosidase for treatment of Fabry disease as enzyme replacement therapy, Clinical safety confirmed in Phase I study.